[Combined effects of PGI2 and thrombin inhibitors or fibrinolytic agent on platelet aggregation and disaggregation].
D001120:Arginine / Q000031:analogs & derivatives; D001550:Benzamidines; D002118:Calcium / Q000494:pharmacology; D004357:Drug Synergism; D011464:Epoprostenol / Q000008:administration & dosage / Q000494:pharmacology*; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006146:Guanidines / Q000494:pharmacology; D006493:Heparin / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D010875:Pipecolic Acids / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D013449:Sulfonamides; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology
D001550:Benzamidines; D005343:Fibrinolytic Agents; D006146:Guanidines; D010875:Pipecolic Acids; D013449:Sulfonamides; D006493:Heparin; D001120:Arginine; D011464:Epoprostenol; D014568:Urokinase-Type Plasminogen Activator; C031942:argatroban; D002118:Calcium; C032855:nafamostat